Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.

Kulikowska de Nalecz, Anna; Ciszak, Lidia; Usnarska-Zubkiewicz, Lidia; Frydecka, Irena; Pawlak, Edyta; Szmyrka, Magdalena; Kosmaczewska, Agata

Kulikowska de Nalecz, Anna; Ciszak, Lidia; Usnarska-Zubkiewicz, Lidia; Frydecka, Irena; Pawlak, Edyta; Szmyrka, Magdalena; Kosmaczewska, Agata.

Affiliation

Kulikowska de Nalecz A; Hematology and Hematological Oncology Department, Provincial Hospital, 45-372 Opole, Poland.
Ciszak L; Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Usnarska-Zubkiewicz L; Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Frydecka I; Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Pawlak E; Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Szmyrka M; Department of Rheumatology and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Kosmaczewska A; Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.

Int J Mol Sci ; 22(17)2021 Aug 27.

Article in En | MEDLINE | ID: mdl-34502204

Subject(s)

CD4-Positive T-Lymphocytes/immunology; CTLA-4 Antigen/metabolism; Gene Expression Regulation, Neoplastic; Lymphocyte Activation/immunology; Multiple Myeloma/mortality; Programmed Cell Death 1 Receptor/metabolism; Receptors, Immunologic/metabolism; Aged; Biomarkers, Tumor/genetics; Biomarkers, Tumor/metabolism; CTLA-4 Antigen/antagonists & inhibitors; CTLA-4 Antigen/genetics; Case-Control Studies; Female; Follow-Up Studies; Humans; Immune Checkpoint Inhibitors/therapeutic use; Immune Tolerance/immunology; Male; Middle Aged; Multiple Myeloma/drug therapy; Multiple Myeloma/immunology; Multiple Myeloma/metabolism; Neoplasm Recurrence, Local/drug therapy; Neoplasm Recurrence, Local/immunology; Neoplasm Recurrence, Local/metabolism; Neoplasm Recurrence, Local/mortality; Prognosis; Programmed Cell Death 1 Receptor/antagonists & inhibitors; Programmed Cell Death 1 Receptor/genetics; Receptors, Immunologic/antagonists & inhibitors; Receptors, Immunologic/genetics; Survival Rate; T-Lymphocytes, Regulatory/immunology; Th17 Cells/immunology

Key words

CD4 T cells; CTLA-4; PD-1; checkpoint inhibitors; clinical outcome; multiple myeloma

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphocyte Activation / Receptors, Immunologic / CD4-Positive T-Lymphocytes / Gene Expression Regulation, Neoplastic / CTLA-4 Antigen / Programmed Cell Death 1 Receptor / Multiple Myeloma Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Int J Mol Sci Year: 2021 Document type: Article Affiliation country: Poland Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google